A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

NCT04068792 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Viruses

Interventions

OTHER: RSV Mobile Application
DRUG: Placebo
DRUG: JNJ-53718678 2.5 mg/kg
DRUG: JNJ-53718678 3 mg/kg
DRUG: JNJ-53718678 4.5 mg/kg

Sponsor

Janssen Research & Development, LLC